Open AccessAssociation of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa
Author(s) -
Jonathan D Cogen,
Frankline Onchiri,
Nicole Hamblett,
Ronald L. Gibson,
Wayne J. Morgan,
Margaret Rosenfeld
Publication year - 2021
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab208
Subject(s) - achromobacter xylosoxidans , medicine , antibiotics , pseudomonas aeruginosa , cystic fibrosis , hazard ratio , pseudomonas infection , proportional hazards model , microbiology and biotechnology , confidence interval , bacteria , biology , genetics
While Pseudomonas aeruginosa (Pa) eradication regimens have contributed to a decline in Pa prevalence in people with cystic fibrosis (CF), this antibiotic exposure might increase the risk of acquisition of drug-resistant organisms. This study evaluated the association between antipseudomonal antibiotic exposure intensity and acquisition risk of drug-resistant organisms among children with CF and new Pa infection.